Literature DB >> 191404

JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships.

B L Padgett, C M Rogers, D L Walker.   

Abstract

JC virus, a human polyomavirus, failed to grow or produce cytopathic effects in any of a variety of cells tested other than primary human fetal glial (PHFG) cells. Cells tested included other primary human cells and glial cells from other animals. Only a rare cell in inoculated insusceptible human cell cultures produced T or virion antigen. In PHFG cell cultures JC virus produced subtle cytopathic effects, and the majority of progeny remained cell associated. Only a few cells in the heterogenous PHFG cell cultures contained T antigen at 24 h postinoculation, and virion antigen was not detected until 48 h postinoculation. The infectivity of JC virus was resistant to inactivation by ether and by heating at 50 degrees C for 1 h. A three-way minor antigenic relationship was demonstrated among the virion antigens of JC virus, BK virus, and simian virus 40 by neurtralization and/or hemagglutination inhibition tests. Serological evidence is presented for the existence of JC virus as a distinct entity before the use of simian virus 40-contaminated poliovirus vaccines and for the nonexistence of an animal reservoir for JC virus infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 191404      PMCID: PMC421416          DOI: 10.1128/iai.15.2.656-662.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

2.  Progressive multifocal leucoencephalopathy: remission with cytarabine.

Authors:  P J Marriott; M D O'Brien; I C Mackenzie; I Janota
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-03       Impact factor: 10.154

3.  Papova virus group.

Authors:  J L MELNICK
Journal:  Science       Date:  1962-03-30       Impact factor: 47.728

4.  [Isolation and ultrastructural study of a Papova type virus not neutralized by the anti SV 40 reference serum during progressive multifocal leukoencephalopathy].

Authors:  F Cathala; J Hauw; R Escourolle
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1973-02-05

5.  Studies of the antigenic relationships of the new human papovaviruses by electron microscopy agglutination.

Authors:  J B Penney; O Narayan
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

6.  Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy.

Authors:  L P Weiner; R M Herndon; O Narayan; R T Johnson; K Shah; L J Rubinstein; T J Preziosi; F K Conley
Journal:  N Engl J Med       Date:  1972-02-24       Impact factor: 91.245

7.  Propagation of human fetal spongioblasts and astrocytes in dispersed cell cultures.

Authors:  H M Shein
Journal:  Exp Cell Res       Date:  1965-12       Impact factor: 3.905

8.  Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.

Authors:  B L Padgett; D L Walker; G M ZuRhein; R J Eckroade; B H Dessel
Journal:  Lancet       Date:  1971-06-19       Impact factor: 79.321

9.  Human papovavirus (JC): induction of brain tumors in hamsters.

Authors:  D L Walker; B L Padgett; G M ZuRhein; A E Albert; R F Marsh
Journal:  Science       Date:  1973-08-17       Impact factor: 47.728

10.  Clonal growth in vitro of human cells with fibroblastic morphology; comparison of growth and genetic characteristics of single epithelioid and fibroblast-like cells from a variety of human organs.

Authors:  T T PUCK; S J CIECIURA; H W FISHER
Journal:  J Exp Med       Date:  1957-07-01       Impact factor: 14.307

View more
  63 in total

Review 1.  Convicting a human tumor virus: guilt by association?

Authors:  J A Blaho; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Restriction endonuclease cleavage map of the DNA of JC virus.

Authors:  J D Martin; R J Frisque; B L Padgett; D L Walker
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

3.  Infectivity of the DNA from four isolates of JC virus.

Authors:  R J Frisque; J D Martin; B L Padgett; D L Walker
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

4.  Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.

Authors:  Biswa Nath Sharma; Manfred Marschall; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

5.  Unusual DNA structure in the regulatory region of the human papovavirus JC virus.

Authors:  S Amirhaeri; F Wohlrab; E O Major; R D Wells
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy.

Authors:  Juliene K G Co; Saguna Verma; Ulziijargal Gurjav; Laarni Sumibcay; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226

7.  Direct isolation and characterization of JC virus from urine samples of renal and bone marrow transplant patients.

Authors:  C Myers; R J Frisque; R R Arthur
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  JC virus-induced changes in cellular gene expression in primary human astrocytes.

Authors:  Sujatha Radhakrishnan; Jessica Otte; Sahnila Enam; Luis Del Valle; Kamel Khalili; Jennifer Gordon
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Identification and characterization of a novel GGA/C-binding protein, GBP-i, that is rapidly inducible by cytokines.

Authors:  G V Raj; K Khalili
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Human fetal Schwann cells support JC virus multiplication.

Authors:  J G Assouline; E O Major
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.